We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (USD)77.89+3.86 (+5.21%)as of 4 Nov 2026
Funds that hold it3One fund per scheme
Held through a master fund30 buy the stock themselves
Largest weight in a single fund3.51%Of that fund's NAV
Median weight2.94%Half the funds hold more than this
What does BBIO do
BridgeBio Pharma, Inc.
Researches and develops drugs for rare genetic diseases, such as heart disease caused by amyloidosis. Most of its revenue comes from newly launched drugs and royalties from partners
Investors in Thailand can buy BBIO through 3 mutual funds open to retail investors. Most of them (3 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds BBIO.
Showing 3 of 3 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
BBIO share price
0.00%
Price change over the selected periodN/A
50-day average
200-day average
Valuation and key ratios
BridgeBio Pharma, Inc. · NASDAQ · Fiscal year ends in January
Market cap15.2B USD0.20 billion shares
P/EN/AFY2025 EPS is negative
Forward P/EN/ABased on forecast 12-month earnings
P/SN/A
EV/EBITDAN/A
Dividend yield0.00%0.00 USD per share a year
ROE41.2%Net profit ÷ shareholders' equity
Debt to equity (D/E)−0.96xInterest-bearing debt
BetaN/AAgainst the S&P 500
Gross margin95.8%FY2025
Operating margin−104.2%FY2025
Net margin−146.0%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S, EV/EBITDA and Beta aren't available for this company yet
Company health made simple
From the FY2025 statements
Sales growth63.6%Fast growth
Yearly average over the last 4 years · Latest annual sales 502.0M USD
Profit from sales−146%Thin margin
For every 100 dollars of sales, about −146 dollars is left as net profit
Dividend0.00%No dividend
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price+26.9%Up
Now 13.6% below its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows 63.6% a year on average · EPS grows N/A a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY202170.0M USD−586.0M USD
FY202278.0M USD−485.0M USD
FY20239.0M USD−653.0M USD
FY2024222.0M USD−543.0M USD
FY2025502.0M USD−733.0M USD
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q2 FY2025111.0M USD−184.0M USD
Q3 FY2025121.0M USD−185.0M USD
Q4 FY2025154.0M USD−195.0M USD
Q1 FY2026195.0M USD−167.0M USD
Q2 FY2026244.0M USD−156.0M USD
Total revenue
Net profit
Annual income statement, balance sheet and cash flow
Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
70.0M USD
78.0M USD
9.0M USD
222.0M USD
502.0M USD
Gross profit
67.0M USD
74.0M USD
7.0M USD
218.0M USD
481.0M USD
Operating profit
−577.0M USD
−512.0M USD
−607.0M USD
−593.0M USD
−523.0M USD
Net profit
−586.0M USD
−485.0M USD
−653.0M USD
−543.0M USD
−733.0M USD
EPS (diluted)
−3.90
−3.26
−3.95
−2.88
−3.78
Gross margin
95.7%
94.9%
77.8%
98.2%
95.8%
Operating margin
−824.3%
−656.4%
−6,744.4%
−267.1%
−104.2%
Net margin
−837.1%
−621.8%
−7,255.6%
−244.6%
−146.0%
Operating cash flow
−498.0M USD
−419.0M USD
−528.0M USD
−521.0M USD
−446.0M USD
Free cash flow
−511.0M USD
−424.0M USD
−529.0M USD
−522.0M USD
−447.0M USD
Total assets
1.0B USD
623.0M USD
546.0M USD
919.0M USD
936.0M USD
Total liabilities
1.9B USD
1.9B USD
1.9B USD
2.4B USD
3.0B USD
Shareholders' equity
−865.0M USD
−1.2B USD
−1.3B USD
−1.5B USD
−2.1B USD
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 77.89 USD on 4 Nov 2026
Daily trendClear uptrendScore 0.50 on a scale of −1 to +1 · 1254 bars
RSI(14)
73.2
ADX(14)
28.7
Position in the price range
68%
Weekly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 262 bars
RSI(14)
57.0
ADX(14)
21.8
Position in the price range
57%
Monthly trendClear uptrendScore 1.00 on a scale of −1 to +1 · 61 bars
RSI(14)
62.9
ADX(14)
37.5
Position in the price range
82%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
71.76
72.59
Above
20 days
68.94
70.65
Above
50 days
69.95
70.91
Above
100 days
74.58
72.03
Above
200 days
72.73
70.38
Above
Indicators (daily)
Indicator
Value
Signal
RSI(14)
73.19
Down
MACD(12,26)
1.68
Up
ADX(14)
28.67
Neutral
ATR(14) % of price
1.62
Neutral
Support and resistance (weekly pivots)
s364
s266
s170
p73
r177
r279
r384
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
Thai funds holding BBIO
3 funds · Highest 3.51% · Median 2.94%
How the weights are spread
Number of funds by weight range
0
2
1
0
0
0
< 1%1–3%3–5%5–8%8–12%12%+
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in BBIO, not the look-through weight · Past performance is not a guarantee of future performance
How Thai money reaches BBIO
3 master funds
Master fund
Thai funds using this route
Master fund's BBIO weight
Janus Henderson Horizon Biotechnology Fund
1
3.51%
several master funds (JHHBIU2 LX, ARKG US)
1
2.94%
several master funds
1
1.37%
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
DAOL-GIHEALTHDAOL GLOBAL INNOVATIVE HEALTHCARE FUND
ASP-IHEALTHAsset Plus Innovative Healthcare Fund
BCAP-XHEALTHBCAP NEXT GEN Health Fund